Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
January 09, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
Libmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe Clinical Type B meeting with U.S. FDA to take place in early 2023...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
January 05, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
December 12, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up Four out of five patients demonstrated gain of cognitive skills in line with...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
December 01, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy®...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
November 14, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
Libmeldy® product sales totaled $4.8M in Q3 and $13.0M YTD with market expansion activities continuing in Europe First case of MLD confirmed from newborn screening study provides critical evidence...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022
November 08, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results
November 07, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
November 03, 2022 09:05 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced early clinical findings from its ongoing proof-of-concept...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
October 10, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
Clinical and pre-clinical data from across the company’s portfolio will be featured in four oral and six poster presentations Co-founder and Chief Executive Officer Bobby Gaspar to give invited talk...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio
August 29, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio...